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Abstract: Amniotic fluid embolism (AFE) is an uncommon obstetric condition involving 
pregnant women during labor or in the initial stages after delivery. Its incidence is 
estimated to be around 5.5 cases per 100,000 deliveries. Therefore, this paper investigated 
the pathophysiological mechanism, which underlies AFE, in order to evaluate the role of 
immune response in the development of this still enigmatic clinical entity. The following 
databases (from 1956 to September 2014) Medline, Cochrane Central, Scopus, Web of 
Science and Science Direct were used, searching the following key words: AFE, 
pathophysiology, immune/inflammatory response, complement and anaphylaxis. The main 
key word “AFE” was searched singularly and associated individually to each of the other 
keywords. Of the 146 sources found, only 19 were considered appropriate for the purpose of 
this paper. The clinical course is characterized by a rapid onset of symptoms, which 
include: acute hypotension and/or cardiac arrest, acute hypoxia (with dyspnoea, cyanosis 
and/or respiratory arrest), coagulopathies (disseminated intravascular coagulation and/or 
severe hemorrhage), coma and seizures. The pathology still determines a significant 
morbidity and mortality and potential permanent neurological sequelae for surviving 
patients. At this moment, numerous aspects involving the pathophysiology and clinical 
development are still not understood and several hypotheses have been formulated,  
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in particular the possible role of anaphylaxis and complement. Moreover, the detection of 
serum tryptase and complement components and the evaluation of fetal antigens can 
explain several aspects of immune response. 
Keywords: amniotic fluid embolism; immune response; mast cell degranulation; 
complement; immunohistochemistry 
 
1. Introduction 
Amniotic fluid embolism (AFE) is an uncommon obstetric condition involving pregnant women 
during labor or in the initial stages after delivery [1,2]. Its incidence is estimated to be around 5.5 cases 
per 100,000 deliveries [3]. 
The clinical course is characterized by a rapid onset of symptoms, which include: acute hypotension 
and/or cardiac arrest, acute hypoxia (with dyspnoea, cyanosis and/or respiratory arrest), coagulopathies 
(disseminated intravascular coagulation and/or severe hemorrhage), coma and seizures [3,4]. 
This pathology is burdened with a high rate of mortality and morbidity and possible permanent 
neurological sequelae for those women who survive [5]. Busardò et al. [6] have reported in a recent 
review a mean mortality rate of 24.8% (±10.96) in affected women, whereas the incidence of AFE in 
pregnancy related deaths was of 12.8% (±6.5) [6]. 
Presently, numerous aspects involving the pathophysiology and clinical development are still not 
understood and several hypotheses have been formulated [7], in particular a possible role of anaphylaxis 
as hypothesized already in 1956 by Attwood [8] and the role of the complement, which was suggested 
for the first time in 1982 by Jacob et al. [9], in the onset of adult respiratory distress as a consequence 
of AFE. Therefore, the aim of this paper is to investigate the pathophysiological mechanism that 
underlies AFE, in order to evaluate the role of the immune response in the development of this still 
enigmatic clinical entity. 
2. Methods 
The following databases (from 1956 to January 2014) Medline, Cochrane Central, Scopus, Web of 
Science and Science Direct were used, searching the following key words: Amniotic fluid embolism 
(AFE), pathophysiology, immune response, complement and anaphylaxis. The main key word “AFE” 
was searched singularly and then associated individually to each of the other keywords. 
Of the 146 sources found, only 19 were considered appropriate for the purpose of this paper.  
All sources have been screened independently by three physicians and in order to be included they had 
to be selected by at least two of them. A flowchart of the papers selected is reported in Figure 1. 
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Figure 1. Flow-chart of the papers selected for the purposes of the study. 
3. Results 
3.1. The Role of β-Tryptase in AFE 
Attwood was the first author [8] to hypothesize in 1956 of a possible anaphylactic reaction in  
the development of AFE in a fatal case involving a 43-year-old woman at her fourth pregnancy.  
Clark et al. [4], several years later in the analysis of the American National registry for AFE, suggested 
a significant similarity of the clinical course and the hemodynamic and laboratory findings between 
women with AFE and subjects with anaphylactic shock, in 46 affected patients after the examination 
of their medical records. 
The anaphylactic reaction as well as septic shock involves the passage into the bloodstream of 
foreign agents (e.g., bacterial endotoxin, certain antigens, etc.), which cause, directly or indirectly,  
the release of numerous endogenous mediators, responsible for the onset of a typical clinical presentation, 
including a profound myocardial depression and decreased cardiac output, pulmonary hypertension 
and disseminated intravascular coagulation (DIC) (Figure 2). 
These clinical and hemodynamic disorders are theoretically indistinguishable from those seen in 
AFE. Moreover, for the first time the term “anaphylactoid” was also introduced, to give a new 
definition of the disease in “a more descriptive manner as anaphylactoid syndrome of pregnancy” [4]. 
Anaphylactoid reactions refer to an identical clinical pattern seen in the classical anaphylaxis, non-IgE 
mediated and certain allergens, including drugs can trigger the mast cell cascade directly without 
involving IgE as the initial mediator [10]. 
Mast cells have a key role in inflammatory and immediate allergic reactions. β-tryptase is a serine 
protease and is the main mediator contained into mast cell granules. The release of β-tryptase from the 
secretory granules is a typical characteristic of mast cell degranulation. Mast cell β-tryptase plays  
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a significant role in inflammation and acts as a marker of mast cell activation; it activates the protease 
activated receptor type 2. There is an increase of serum mast cell β-tryptase levels both in anaphylaxis 
and in other allergic states and is strongly indicative of an immunologically mediated reaction even 
though it can also happen after a direct activation of mast cells [11]. 
 
Figure 2. The immuno-inflammatory pathogenesis and the target organs. (A) Evidence of 
fetal squamous cells, lanugo hairs, vernix caseosa, in the pulmonary artery vasculature 
(Hematoxylin-eosin staining, 200×); (B) AE1/AE3 cytokeratin stains on the lungs showed 
intense intravascular positivity of fetal squamous cells; (C) Lanugo hairs and nuclei of fetal 
squamous cells are clearly visible (confocal laser scanning microscope); (D) Mucin 
fluoresced (in red) in the pulmonary capillary septa (confocal laser scanning microscope); 
(E) Pulmonary capillary septa: evidence of degranulating mast cells with tryptase-positive 
material outside the cells (Ab anti-tryptase); (F,G) Degranulating mast cells with  
tryptase-positive material outside the cells (confocal laser scanning microscope). Figures 
extracted from cases previously published by Fineschi et al. [12]. 
Regarding the role of mast cell degranulation in the physiopathological mechanism of AFE, different 
considerations should be placed concerning serological and histological findings. In two different 
reports [12,13], the Authors detected serum tryptase levels in fatal cases of AFE and the following 
concentrations were found: 47.2 [12] and 67.2 ng/mL [13]. 
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In comparing both values to the control group of Nishio et al. [13], which was composed of 11 
cases (three pulmonary embolisms, three traffic accidents, two strangulations, two throttling cases and 
one anaphylactic shock), the results showed that apart from the case of anaphylactic shock, in which 
the serum tryptase concentration was 648 ng/mL (17.7 and 9.6 times, respectively, higher than AFE 
cases), for the remaining 10 controls the mean concentration was of 6.8 ng/mL (range 3.4–9.8 ng/mL),  
which is 6.9 and 9.9 times, respectively, lower than the two AFE cases. The data above regarding 
serum tryptase levels seem to support a mast cell degranulation in the physiopathological mechanism 
of AFE, taking into account the upper normal limits for tryptase concentrations in serum proposed by 
Edston et al. [14] of 44.3 ng/mL. Moreover, according to Mayer et al. [15], while moderately elevated 
tryptase levels are common in post mortem sera, values above 45 ng/mL may support the diagnosis of 
fatal anaphylaxis. 
However, other reports of AFE cases, in which serum tryptase was detected, gave discordant results 
to the anaphylactic hypothesis. 
A 40-year-old woman experienced an acute onset of facial erythema, eclampsia-type seizures, 
severe hypoxia, cardiac arrest and DIC while in early active labor. The patient died almost 40 min after 
the onset of symptoms. The autopsy followed by a histological examination showed fetal squames 
within the pulmonary tree, uterine blood vessels and brain. A peripheral venous blood specimen, obtained 
approximately one and a half hours postmortem, revealed a tryptase level of 4.7 ng/mL [16]. This level 
falls within the normal post mortem serum tryptaserange, which does not support the diagnosis. 
Benson et al. [17], in the analysis of a series of cases involving nine women with “presumed” 
amniotic fluid embolism and a control group of 22 women who had had a normal labor, detected serum 
levels of tryptase, urinary histamine concentrations, and serum levels of a fetal antigen; the results 
obtained were negative for serum tryptase and urinary histamine measurements in women with AFE. 
Different considerations should be placed regarding mast cell degranulation in lungs. In a study 
from 1998 [18], the authors examined the presence and the pulmonary distribution of mast cell tryptase 
utilizing specific immunohistochemical studies and morphometric evaluation in six fatal cases of AFE, 
compared to six subjects who died following anaphylactic shock and two control groups (five and  
six cases, respectively) of traumatic deaths. The results demonstrated a numerical increase of pulmonary 
mast cells in the subjects who died of AFE (average cell number 54,095) with values corresponding to 
those encountered in the cases of death due to anaphylactic shock (average cell number 51,378) 
compared with that of the traumatic control groups (average cell number 24,477 and 9995, respectively).  
In a more recent paper from 2009 [12], a similar approach was applied and the results obtained showed 
a large increase in extracellular tryptase consistent with mast cell degranulation in the eight women in 
the AFE group compared to a control group composed of six pregnant women who died as a result of 
traumatic injuries. These studies, therefore, highlight that mast cell degranulation occurs in the lungs of 
AFE fatal cases, whereas it does not occur in other fatal pregnancies. 
3.2. The Role of Complement in AFE 
Hammerschmidt et al. [19], in a report from 1984 involving a “30-year-old woman died with massive 
pulmonary microvascular leukostasis immediately after cesarean hysterectomy”, have postulated the 
hypothesis of complement activation in the physiopathological mechanism of AFE. 
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More recently, Benson et al. [17] in the group of eight women with AFE already discussed, detected 
C3 and C4 levels in serum samples and the results of these analyses showed abnormally low levels of 
complement. Mean C3 level of 44.0 mg/dL and C4 level of 10.7 mg/dL were significantly lower than 
corresponding postpartum control values of 117.3 and 29.4 mg/dL. Moreover, postpartum C3 and C4 
levels decreased by 8% and 5%, respectively, compared with intrapartum values but they were still 
within the normal range [17]. In the fatal case of AFE reported by Nishio et al. [13], serum C3  
and C4 levels showed the following concentrations: 74 and 16 mg/dL, respectively. These values were 
lower than reported postpartum control values of Benson et al. [17] and they are, therefore, significantly 
suggestive of complement activation. It is important to take into consideration complement levels 
during normal pregnancies. A study involving ten women in labor found that complement levels 
remained normal, whereas a more comprehensive view of complement was obtained in two additional 
groups of normal parturients, in which complement levels were drawn several times during labor and 
then again immediately post-partum. The results showed that complement components did not undergo 
a significant change during labor, while there was a statistically significant drop in the minutes after 
birth [26,27]. Fineschi et al. [12], in the analysis of eight fatal cases of AFE, adopted a diagnostic 
immunohistochemical approach using anti-C3a antibodies and the levels of complement C3a were 
twofold lower in AFE cases than in the control cases, suggesting a possible complement activation in 
the physiopathology of the disease (Figure 3). A complement activation reaction to sialyl-Tn (STN) 
may explain the mechanism of the disease [12]. STN is a known component of meconium and mucin 
deriving from amniotic fluid. The detection of STN antigen in the serum of patients with suspected 
AFE constitutes a direct diagnostic method in confirming that the release of amniotic fluid-derived 
mucin has crossed over into the maternal circulation [20,21]. Complement activation was found along 
with high levels of STN and levels of complement C3 and C4 were two- to threefold lower than 
normal [17]. The complement system can be activated by three biochemical pathways: the classical, 
the alternative and the lectin pathway, which generate homologous variants of the protease C3-convertase; 
both C3 and C4 are involved in the classical pathway of complement, which normally requires antigen: 
antibody complexes (immune complexes) for activation. The classical pathway is characterized by  
the activation of the C1-complex, which then splits C4 and C2 with the formation of C4b2a complex 
(C3-convertase). The classical pathway C3-convertase cleaves C3 into C3a and C3b, determining a 
cascade of additional cleavage and activation events. Although the involvement of C3 and C4 is 
suggestive of the activation of the classical pathway of complement [27], the alternative complement 
pathway cannot be excluded [19]. 
In a recent case presented by Hikiji et al. [22], involving a 39-year-old woman who died during 
delivery after a normal 40-week second pregnancy, the authors after a complete post mortem examination, 
performed an immunohistochemical staining for C5a receptor (C5aR), which was positive in stromal 
cells around the pulmonary capillaries and inflammatory cells in alveolus. Moreover, they detected 
concentrations of ZnCP-I and STN significantly higher than the normal values (72.5 pmol/mL and 
2630 U/mL, respectively). These findings are consistent with a recent paper by Toro et al. [23],  
who introduced C5aR stain as a helpful technique to prove the complement activation and anaphylatoxin 
formation and at the same time they support the hypothesis of complement activation initiated by fetal 
antigens leaking into the maternal circulation [12]. In a recently published study by Tamura et al. [24], 
the authors measured C1 esterase inhibitor (C1INH) activity levels in 106 AFE cases (21 of which 
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were fatal) and the results obtained were compared to a control group composed of 88 women, without 
AFE and any medical intervention except general birth and surgical assistance. The comparison of the 
two groups highlighted C1INH activity levels in the AFE cases that were significantly lower than those 
in the controls (p < 0.0001). Moreover, a statistically significant difference (p = 0.0121) in C1INH 
activity levels between fatal (22.5% ± 3.4%) and nonfatal AFE cases (32.0% ± 2.1%) was found. 
 
Figure 3. Histopatological findings. (A) Pulmonary mast cells with anti-tryptase reactions; 
(B) Degranulating mast cells mast cells present in a bronchial wall (Ab anti-tryptase);  
(C) Evidence of degranulating mastcells with tryptase-positive material outside the cells 
(Ab anti-tryptase); (D) Confocal laser scanning microscope: weak expression (head-arrow) 
of complement C3a in an AFE case. Figures extracted from cases previously published by 
Fineschi et al. [12]. 
C1INH represents the major inhibitor of C1 esterase but also of coagulation factor XII activation 
(FXIIa) and kallikrein [28,29]; therefore, it is able not only to inhibit the complement system but also 
to modulate the coagulofibrinolytic and kallikrein-kinin systems [30,31]. From a clinical point of view, 
DIC is considered one of the most common symptoms in AFE patients, and FXII may be involved in 
its onset because it is activated by several biological and non-biological negatively charged surfaces, 
determining blood coagulation and the activation of the complement and the kallikrein-kinin system in 
order to produce bradykinin [32], which has vasodilation effects, a hypotensive effect and causes an 
increase in vascular permeability resulting in a hypotonic uterus [33,34]. Moreover, FXII is also able 
to inactivate plasminogen activator inhibitor 1 and enhance fibrinolysis [35]. These evidences are 
suggestive of the FXII involvement after its activation by contact in the pathophysiological mechanism 
of AFE. The study of Tamura and colleagues [24], demonstrates that C1INH activity levels in AFE 
cases were significantly lower than those of controls, especially in fatal cases, suggesting that C1INH 
levels may be related to the severity of the pathology and may represent a prognostic factor. 
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4. Discussion and Conclusions 
Presently, the data available about the significance of serum tryptase is too limited to draw exhaustive 
conclusions and the absence of suitable animal models do not allow this process. Only by performing a 
systematic analysis of all cases may we clarify some issues. Moreover, in order to obtain more reliable 
results in the detection of serum tryptase, the post mortem interval (PMI) should be considered [36,37]. 
Horn et al. [36] analyzed serum levels of tryptase from 57 decedents with varying PMI, who all died of 
presumed non-anaphylactic causes. Average values of serum tryptase within 10-h increments of PMI 
were calculated and the results obtained demonstrated significant elevations with increasing PMI and 
the best results in terms of stability were obtained within five hours of death. Therefore, blood samples 
in fatal cases of AFE should be collected as soon as possible after death, in order to reduce post 
mortem variations in tryptase concentrations. 
Regarding evidence of mast cell degranulation in the maternal pulmonary vasculature, the results so 
far achieved, allow us to confirm that mast cell degranulation does take place in the lungs in fatal AFE 
cases and does not do so in other mortal pregnancy conditions [38]. In this regard, however, other aspects 
concerning pulmonary mast cell involvement need to be clarified, e.g., if it is a primary mechanism of 
AFE or a secondary process and if mast cell degranulation can happen as a result of complement 
activation. Complement activation products C3a and C5a are anaphylatoxic peptides released from the 
amino terminus of the α-chain of the genetically linked components C3 and C5. They bind to the high 
affinity Immunoglobulin E receptor (FcεRI) expressed on the cell membrane of mast cells, determining 
their activation and degranulation [39]. 
Considering the role of complement in the physiopathology of AFE, several studies agree with its 
involvement, both directly through the activation of the classical pathway or indirectly by the release 
of anaphylatoxic peptides, therefore, in the near future with the findings of more studies, it may 
become a reliable diagnostic marker. 
Presently, the diagnosis of AFE is principally based on clinical observation of symptoms; therefore 
rapid diagnosis and immediate interdisciplinary treatment are essential for a good outcome [40]. For those 
women, who do not survive, a complete autopsy supported by histological and immunohistochemical 
analysis is fundamental. Moreover, the detection of serum tryptase and complement components and 
the evaluation of fetal antigens can explain several aspects of immune response, which are still obscure 
in the development of this pathology [41]. 
However, although immunological profiling studies may be the best choice in this difficult process [42], 
several other biomarkers should be better investigated in order to formulate a prompt diagnosis of AFE. 
The modern techniques of molecular biology and proteomics could also represent a valid tool in 
implementing the traditional laboratory tests currently available. The most suitable biomarker should 
include these features: non-invasive and easy to sample, specific and distinguishable from those 
naturally present during pregnancy and finally the level of specificity and sensitivity has to be enough 
to avoid false positive and/or negative results [25]. A list of biomarkers potentially or presently 
available [26,43–61] is reported in Table 1. 
Advances in the understanding of the physiopathological mechanism of AFE, can help the diagnosis 
and therefore the treatment. This aim can be achieved by a proper assessment and classification of all 
cases, in the attempt to clarify numerous pathophysiological aspects in order to set the best standard of 
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care possible in the management of these problematic patients with the objective of reducing the 
mortality rates and the incidence of permanent damage [61]. If on the one hand growing evidences 
suggest the activation of the immune system at different levels in the pathophysiology of the disease, 
on the other one, what remains an open question is “Why don’t all mothers develop an immune response 
to their fetuses?” Presently, immune tolerance, especially during pregnancy shows many obscure points; 
indeed, it is proved that the passage of fetal material into the maternal circulation regularly occurs 
without causing any damage to both mother and fetus [27]. 
Table 1. Biomarkers potentially or presently available for the diagnosis of AFE. 
Biomarkers Applications 
Activin A Maternal serum and amniotic fluid levels of Activin A have 
been shown to increase with gestational age.  
The AF-to-MS serum ratio for Activin was 5:1. 
Brain natriuretic peptide (BNP) It is approximately 50-times more concentrated in the AF 
than it is in the MS.  
It is usually elevated after any pulmonary event/insult.  
It is a non-specific marker. 
CA125 It is 100 times more concentrated in AF when compared to 
normal MS. Further investigations are required. 
Carcinoembryonic antigen (CEA) It has been found in AF at concentrations in excess of  
200 times those of normal MS, but further investigations  
are required. 
Chromogranin A (CgA) It is 2.5 times more concentrated in the AF than in MS,  
but this difference may not be specific since it can fluctuate 
depending on the trimester of the pregnancy. 
Endothelin It has been found to be significantly elevated in rabbits 
following the infusion of meconium-stained amniotic fluid. 
Fetal cell identification in maternal circulation Only about 50% of patients with AFE had fetal products 
detected. The presence of squamous cells in the  
maternal pulmonary artery circulation is no longer 
considered pathognomonic. 
Insulin-like growth factor binding protein 1 
(IGFBP-1) 
It is 150 times more concentrated in AF than in MS making 
it potentially useful. 
Interleukin-6, Interleukin-8, Tumor Necrosis 
Factor-alpha-soluble receptor p55 (sTNFp55) 
Significantly higher in AF than in MS, they can be useful 
markers in diagnosing AFE in the presence of maternal 
systemic inflammatory response syndrome. 
Procollagen type I N-terminal propeptide 
(PINP) 
It is approximately 450 times more concentrated in AF  
than MS, newer methods of assessment of PINP are  
being developed. 
Pro-early placenta insulin-like peptide  
(Pro-EPIL) 
It is 10 times more concentrated in the AF when compared 
to MS, it is higher in women with pathologic conditions. 
Pro-opiomelanocortin (POMC) It is 10-times more concentrated in the AF than in MS.  
High concentrations at the feto-maternal interface make it a 
potential biomarker of AFE. 
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Table 1. Cont. 
Biomarkers Applications 
Prostate-specific antigen (PSA) The PSA concentration increases with gestational age from  
11 to 21 weeks, stabilizes, and then decreases at delivery.  
This variability makes its use as a biomarker for AFE  
more difficult. 
Sialosyl Tn (STN) It constitutes a direct diagnostic method of confirming the 
presence of AF-derived mucin into the maternal circulation.  
It may be prognostic in maternal mortality. 
Squamous cell carcinoma (SCC) antigen It is known to be released from fetal epidermis and was found 
in amniotic fluid samples at concentrations over 410 times 
greater than in maternal serum. 
Tissue polypeptide-specific (TPS) antigen It is 10–20 times more concentrated in AF than in MS Its use as 
a biomarker for AFE requires extensive additional work. 
TKH-2 It represents a more sensitive method of detecting meconium 
and AF-derived mucin in the lung secretions of patients with 
AFE, in over 90% of cases. 
Zinc Coproporphyrin 1 (ZnCP-1) It has been found to be significantly elevated in patients with AFE. 
It is a noninvasive and sensitive method for diagnosing AFE. 
AF: Amniotic fluid; MS: Maternal serum; AFE: Amniotic fluid embolism. 
Amniotic fluid embolism currently remains not only a clinical nightmare [62], but also an open 
interdisciplinary challenge [40], which needs the support of obstetricians, intensive care physicians, 
forensic pathologists and even immunologists. 
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